Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

476475 PKC Inhibitor, EGF-R Fragment 651-658, Myristoylated - Calbiochem

The PKC Inhibitor, EGF-R Fragment 651-658, Myristoylated controls the biological activity of PKC. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

同义词: Myr-N-RKRTLRRL-OH, Myristoylated EGF-R Fragment (651-658), Protein Kinase C Inhibitor, Protein Kinase C Inhibitor, EGF-R Fragment 651-658, Myristoylated

Primary Target: PKC
476475
Purchase on Sigma-Aldrich

概述

Replacement Information

重要规格表

Empirical Formula
C₆₀H₁₁₇N₂₁O₁₁

Products

产品目录编号包装 数量 / 包装
476475-500UGCN 塑胶安瓿;塑胶针药瓶 500 μg
Description
OverviewEpidermal growth-factor receptor (EGF-R) conserved sequence which is identical to v-ErbB (95-102). An N-terminal myristoylated membrane-permeable, reversible, and substrate competitive inhibitor of protein kinase C (IC50 = 5 µM).
Catalogue Number476475
Brand Family Calbiochem®
SynonymsMyr-N-RKRTLRRL-OH, Myristoylated EGF-R Fragment (651-658), Protein Kinase C Inhibitor, Protein Kinase C Inhibitor, EGF-R Fragment 651-658, Myristoylated
References
ReferencesWard, N.E., and O’Brian, C.A. 1993. Biochemistry 32, 11903.
O’Brian, C.A., et al. 1991. Invest. New Drugs 9, 169.
Product Information
ATP CompetitiveN
FormLyophilized solid
FormulationSupplied as a trifluoroacetate salt.
Hill FormulaC₆₀H₁₁₇N₂₁O₁₁
Chemical formulaC₆₀H₁₁₇N₂₁O₁₁
Hygroscopic Hygroscopic
ReversibleY
Sold on the basis of peptide contentY
Quality LevelMQ100
Applications
Biological Information
Primary TargetPKC
Primary Target IC<sub>50</sub>5 µM against protein kinase C
Purity≥97% by HPLC
Physicochemical Information
Cell permeableY
Peptide ContentY
Peptide SequenceMyr-N-Arg-Lys-Arg-Thr-Leu-Arg-Arg-Leu-OH
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage -20°C
Protect from Moisture Protect from moisture
Hygroscopic Hygroscopic
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
产品目录编号 GTIN
476475-500UGCN 04055977183818

Documentation

PKC Inhibitor, EGF-R Fragment 651-658, Myristoylated - Calbiochem MSDS

职位

物料安全数据表 (MSDS) 

PKC Inhibitor, EGF-R Fragment 651-658, Myristoylated - Calbiochem 分析证书

标题批号
476475

参考

参考信息概述
Ward, N.E., and O’Brian, C.A. 1993. Biochemistry 32, 11903.
O’Brian, C.A., et al. 1991. Invest. New Drugs 9, 169.
数据表

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision11-January-2010 RFH
SynonymsMyr-N-RKRTLRRL-OH, Myristoylated EGF-R Fragment (651-658), Protein Kinase C Inhibitor, Protein Kinase C Inhibitor, EGF-R Fragment 651-658, Myristoylated
DescriptionEpidermal growth-factor receptor (EGF-R) conserved sequence which is identical to v-erbB (95-102). An N-terminal myristoylated membrane-permeable, reversible, and substrate competitive inhibitor that inhibits protein kinase C (IC50 = 5 µM) in intact cells.
FormLyophilized solid
FormulationSupplied as a trifluoroacetate salt.
Chemical formulaC₆₀H₁₁₇N₂₁O₁₁
Peptide SequenceMyr-N-Arg-Lys-Arg-Thr-Leu-Arg-Arg-Leu-OH
Purity≥97% by HPLC
SolubilityH₂O (5 mg/ml)
Storage Protect from moisture
-20°C
Hygroscopic
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.
Toxicity Standard Handling
ReferencesWard, N.E., and O’Brian, C.A. 1993. Biochemistry 32, 11903.
O’Brian, C.A., et al. 1991. Invest. New Drugs 9, 169.